Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention is directed to novel compounds possessing both angiotensin converting enzyme inhibitory activity and neutral endopeptidase inhibitory activity and methods of preparing such compounds.
• the present invention is also directed to pharmaceutical compositions containing such dual inhibiting compounds or pharmaceutically acceptable salts thereof and their use in the manufacture of medicaments.
• Angiotensin-Converting Enzyme is a peptidyl dipeptidase which catalyzes the conversion of angiotensin I to angiotensin II.
• Angiotensin II is a vasoconstrictor which also stimulates aldosterone secretion by the adrenal cortex.
• ACE inhibition prevents both the conversion of angiotensin I to angiotensin II and the metabolism of bradykinin, resulting in decreased circulating angiotensin II, aldosterone and increased circulating bradykinin concentrations. In addition to these neurohormonal changes, decreases in peripheral resistance and blood pressure are observed, particularly in individuals with high circulating renin.
• Other pharmacological effects associated with ACE inhibition include regression of left ventricular hypertrophy, improvement in the clinical signs of heart failure, and reduction in mortality in patients with congestive heart failure (CHF) or left ventricular dysfunction after myocardial infarction.
• CHF congestive heart failure
• Neutral endopeptidase is an enzyme responsible for the metabolism of atrial natriuretic peptide (ANP). Inhibition of NEP results in increased ANP concentrations, which in turn leads to natriuresis, diuresis and decreases in intravascular volume, venous return and blood pressure. ANP is released by atrial myocytes in response to atrial stretch or increased intravascular volume. Elevated plasma concentrations of ANP have been demonstrated as a potential compensatory mechanism in various disease states, including congestive heart failure, renal failure, essential hypertension and cirrhosis.
• U.S. patent 5,430,145 discloses tricyclic mercaptoacetylamide derivatives useful as ACE and NEP inhibitors.
• the present invention relates to specific compounds covered by the generic disclosure of U.S. patent 5,430,145 which have surprisingly improved ADME ( Absorption, Distribution, Metabolism, Excretion) properties over the compounds exemplified therein.
• ADME Absorption, Distribution, Metabolism, Excretion
• Ri is hydrogen, -CH 2 OC(O)C(CH 3 ) 3 , or an acyl group
• R 2 is hydrogen; -CH 2 O-C(O)C(CH 3 ) ; a C r C 4 -alkyl; aryl, aryl-(C ⁇ -C 4 -alkyl); or diphenylmethyl;
• X is -(CH 2 ) n wherein n is an integer 0 or 1 , -S- , -O- ,
• R 3 is hydrogen, a C ⁇ -C -alkyl, aryl or aryl-(C ⁇ -C -alkyl) and R 4 is -CF 3 , C 1 -C 10 - alkyl, aryl, or aryl-(CrC -alkyl);
• B 1 and B 2 are each independently hydrogen, hydroxy, or -OR 5 , wherein R 5 is C ⁇ -C 4 - alkyl, aryl, or aryl-(C ⁇ -C 4 -alkyl) or, where B-i and B 2 are attached to adjacent carbon atoms, B 1 and B 2 can be taken together with said adjacent carbon atoms to form a benzene ring or methylenedioxy.
• the present invention provides a compound of the formula I wherein R* ⁇ is acetyl. In another embodiment, the present invention provides a compound of the formula I wherein R 1 is hydrogen. In a further embodiment, the present invention provides a compound of the formula I wherein R 2 is hydrogen. In a further embodiment, the present invention provides a compound of the formula I wherein B 1 and/or B 2 are hydrogen. In yet a further embodiment, the present invention provides a compound of the formula I wherein X is -CH 2 .
• the present invention provides a compound of formula I A:
• Ri is acetyl or hydrogen
• the compounds of the formula I are particularly useful as dual inhibitors of ACE and NEP.
• the present invention accordingly provides a pharmaceutical composition comprising an effective ACE and/or NEP inhibiting amount of a compound of formula I in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.
• 'C ⁇ -C -alky refers to a saturated straight or branched monovalent hydrocarbon chain of one, two, three or four carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, and the like groups.
• 'CrCio-alkyl' refers to a saturated straight or branched monovalent hydrocarbon chain of one to ten carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, pentyl, isopentyl, hexyl, 2,3-dimethyl-2-butyl, heptyl, 2,2- dimethyl-3-pentyl, 2-methyl-2-hexyl, octyl, 4-methyl-3-heptyl and the like groups.
• 'aryl' refers to a phenyl or naphthyl group unsubstituted or substituted with from one to three substituents selected from the group consisting of methylenedioxy, hydroxy, C- ⁇ -C -alkoxy, fluoro and chloro. Included within the scope of the term 'aryl-(C ⁇ -C 4 -alkyl)' are phenylmethyl (benzyl), phenylethyl, p-methoxybenzyl, p-fluorobenzyl and p-chlorobenzyl.
• 'C ⁇ -C -alkoxy' refers to a monovalent substitutent which consists of a straight or branched alkyl chain having from 1 to 4 carbon atoms linked through an ether oxygen atom and having its free valence bond from the ether oxygen, and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy and the like groups.
• 'heterocycle means any closed-ring moiety in which one or more of the atoms of the ring are an element other than carbon and includes, but is not limited to, the following: piperidinyl, pyridinyl, isoxazolyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, benzimidazolyl, thiazolyl, thienyl, furanyl, indolyl, 1 ,3- benzodioxolyl, tetahydropyranyl, imidazolyl, tetrahydrothienyl, pyranyl, dioxanyl, pyrrolyl, pyrimidinyl, pyrazinyl, thiazinyl, oxazolyl, purinyl, quinolinyl and isoquinolinyl.
• 'halogen' or 'Hal' refers to a member of the family of fluorine, chlorine, bromine or iodine.
• acyl group' refers to aliphatic and aromatic acyl groups and those derived from heterocyclic compounds.
• the acyl group may be a lower or (C ⁇ -C 4 )alkanoyl group such as formyl or acetyl, an aroyl group such as benzoyl or a heterocyclic acyl group comprising one or more of the heteroatoms O, N and S, such as the group
• stereoisomer' is a general term used for all isomers of individual molecules that differ only in the orientation of their atoms in space.
• stereoisomer includes mirror image isomers (enantiomers), geometric (cis/trans or E/Z) isomers, and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereoisomers).
• 'R' and 'S' are used as commonly used in organic chemistry to denote specific configuration of a chiral center.
• the term 'R' (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
• the term 'S' (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
• the priority of groups is based upon sequence rules wherein prioritization is first based on atomic number (in order of decreasing atomic number). A listing and discussion of priorities is contained in Stereochemistry of Organic Compounds, Ernest L. Eliel, Samuel H. Wilen and Lewis N. Mander, editors, Wiley-lnterscience, John Wiley & Sons, Inc., New York, 1994.
• the older D-L system may also be used herein to denote absolute configuration, especially with reference to amino acids.
• a Fischer projection formula is oriented so that the number 1 carbon of the main chain is at the top.
• the prefix 'D' is used to represent the absolute configuration of the isomer in which the functional (determing) group is on the right side of the carbon at the chiral center and 'L', that of the isomer in which it is on the left.
• 'treat' or 'treating' means any treatment, including but not limited to, alleviating symptoms, eliminating the causation of the symptoms either on a temporary or permanent basis, or to preventing or slowing the appearance of symptoms and progression of the named disease, disorder or condition.
• the term 'patient' refers to a warm blooded animal such as a mammal which is afflicted with a particular disease, disorder or condition. It is explicitly understood that guinea pigs, dogs, cats, rats, mice, horses, cattle, sheep, and humans are examples of animals within the scope of the meaning of the term.
• the term 'pharmaceutically acceptable salt' is intended to apply to any salt, whether previously known or future discovered, that is used by one skilled in the art that is a non-toxic organic or inorganic addition salt which is suitable for use as a pharmaceutical.
• Illustrative bases which form suitable salts include alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium or magnesium hydroxides; ammonia and aliphatic, cyclic or aromatic amines such as methylamine, dimethylamine, triethylamine, diethylamine, isopropyldiethylamine, pyridine and picoline.
• Illustrative acids which form suitable salts include inorganic acids such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric and like acids, and organic carboxylic acids such as, for example, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic and dihydroxymaleic, benzoic, phenylacetic, 4-aminobenzoic, 4-hydroxybenzoic, anthranilic, cinnamic, salicylic, 4-aminosalicylic, 2-phenoxybenzoic, 2-acetoxybenzoic, mandelic and like acids, and organic sulfonic acids such as methanesulfonic and p- toluenesulfonic acids.
• inorganic acids such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric and like acids
• organic carboxylic acids such as, for example,
• 'pharmaceutical carrier refers to known pharmaceutical excipients useful in formulating pharmaceutically active compounds for administration, and which are substantially nontoxic and nonsensitizing under conditions of use. The exact proportion of these excipients is determined by the solubility and chemical properties of the active compound, the chosen route of administration as well as standard pharmaceutical practice.
• the appropriate phthalimide blocked (S)-phenylalanine derivative of structure 2 can be prepared by reacting the appropriate (S)-phenylalanine derivative of structure 1 with phthalic anhydride in a suitable aprotic solvent, such as dimethylformamide.
• step b the appropriate phthalimide blocked (S)-phenylalanine derivative of structure 2 can be converted to the corresponding acid chloride, then reacted with the appropriate amino acid methyl ester of structure 3 in a coupling reaction.
• the appropriate phthalimide blocked (S)-phenylalanine derivative of structure 2 can be reacted with oxalyl chloride in a suitable aprotic solvent, such as methylene chloride.
• the resulting acid chloride can then be coupled with the appropriate amino acid methyl ester of structure 3 using a suitable base, such as N-methylmorpholine in a suitable aprotic solvent, such as dimethylformamide, to give the appropriate 1-oxo-3- phenylpropyl-a ino acid methyl ester derivative of structure 4.
• a suitable base such as N-methylmorpholine
• a suitable aprotic solvent such as dimethylformamide
• the hydroxymethylene functionality of the appropriate 1-oxo-3-phenylpropyl- amino acid methyl ester derivative of structure 4 can be oxidized to the appropriate aldehyde of structure 5 by oxidation techniques well known and appreciated in the art.
• the hydroxymethylene functionality of the appropriate 1-oxo-3- phenylpropyl-amino acid methyl ester derivative of structure 4 can be oxidized to the appropriate aldehyde of structure 5 by means of a Swern oxidation using oxalyl chloride and dimethylsulfoxide in a suitable aprotic solvent, such as methylene chloride.
• the appropriate aldehyde of structure 5 can be cyclized to the appropriate enamine of structure 6 by acid catalysis.
• the appropriate aldehyde of structure 5 can be cyclized to the appropriate enamine of structure 6 by treatment with trifluoroacetic acid in a suitable aprotic solvent, such as methylene chloride.
• the appropriate enamine of structure 6 can be converted to the corresponding tricyclic compound of structure 7 by an acid catalyzed Friedel-Crafts reaction.
• the appropriate enamine of structure 6 can be converted to the corresponding tricyclic compound of structure 7 by treatment with a mixture of trifluoromethane sulfonic acid and trifluoroacetic anhydride in a suitable aprotic solvent, such as methylene chloride.
• step e it may be necessary to reesterify the carboxy functionality due to the conditions of the work-up.
• a suitable aprotic solvent such as dimethyl-formamide
• a non-nucleophilic base such as cesium carbonate
• the phthalimide protecting group of the appropriate tricyclic compound of structure 7 can be removed using techniques and procedures well known in the art.
• the phthalimide protecting group of the appropriate tricyclic compound of structure 7 can be removed using hydrazine monohydrate in a suitable protic solvent such as methanol, to give the corresponding amino compound of structure 8.
• the appropriate (S)-acetate compound of structure 10 can be prepared by reacting the appropriate amino compound of structure 8 with the appropriate (S)- acetate of structure 9.
• the appropriate amino compound of structure 8 can be reacted with the appropriate (S)-acetate compound of structure 9 in the presence of a coupling reagent such as EEDQ (1-ethoxycarbonyl-2-ethoxy-1 ,2- dihydroquinoline), DCC (1 ,3-dicyclohexylcarbodiimide), or diethylcyanophosponate in a suitable aprotic solvent, such as methylene chloride to give the appropriate (S)-acetoxy compound of structure 10.
• a coupling reagent such as EEDQ (1-ethoxycarbonyl-2-ethoxy-1 ,2- dihydroquinoline), DCC (1 ,3-dicyclohexylcarbodiimide), or diethylcyanophosponate in a suitable aprotic solvent, such as methylene chloride to give
• step h the (S)-acetate functionality of the appropriate amide compound of structure 10 can be hydrolyzed to the corresponding (S)-alcohol of structure 11a with a base, such as lithium hydroxide in a suitable solvent mixture, such as tetrahydrofuran and ethanol.
• a base such as lithium hydroxide in a suitable solvent mixture, such as tetrahydrofuran and ethanol.
• step i the (S)-alcohol functionality of the appropriate amide compound of structure 11a can be converted to the corresponding (R)-thioacetate or (R)-thiobenzoate of structure 12a.
• the appropriate (S)-alcohol of structure 11a can be treated with thiolacetic acid in a Mitsunobu reaction using triphenylphosphine and DIAD (diisopropylazodicarboxylate) in a suitable aprotic solvent, such as tetrahydrofuran.
• step j the (S)-alcohol functionality of the appropriate amide compound of structure 11 a can be converted to the corresponding (R)-alcohol of structure 11 b.
• the appropriate (S)-alcohol of structure 11a can be treated with acetic acid in a Mitsunobu reaction using triphenylphosphine and DIAD in a suitable aprotic solvent, such as tetrahydrofuran.
• the resulting (R)-acetate can then be hydrolyzed with a suitable base, such as lithium hydroxide.
• step k the (R)-alcohol functionality of the appropriate amide compound of structure 11b can be converted to the corresponding (S)-thioacetate or (S)-thiobenzoate of structure 12b.
• the appropriate (R)-alcohol of structure 11b can be treated with thiolacetic acid in a Mitsunobu reaction using triphenylphosphine and DIAD in a suitable aprotic solvent, such as tetrahydrofuran.
• the R-i and R 2 groups on the compounds of structures 12a and 12b can be manipulated using techniques and procedures well known and appreciated by one of ordinary skill in the art to give the corresponding compounds of structures 13a - 14a and 13b - 14b.
• the diphenylmethyl ester functionality of the appropriate compound of structure 12a can be removed using trifluoroacetic acid to give the appropriate carboxylic acid compound of structure 13a.
• the diphenylmethyl ester functionality of the appropriate compound of structure 12b can be removed using trifluoroacetic acid to give the carboxylic acid compound of structure 13b.
• the (R)-thioacetate or (R)-thiobenzoate functionality of the appropriate compound of structure 13a can be removed with lithium hydroxide in a suitable solvent mixture such as tetrahydrofuran and ethanol to give the appropriate (R)-thio compound of structure 14a.
• the (S)-thioacetate or (S)-thiobenzoate functionality of the appropriate compound of structure 13b can be removed with lithium hydroxide in a suitable solvent mixture such as tetrahydrofuran and ethanol to give the appropriate (S)-thio compound of structure 14b.
• the present invention provides a process for the preparation of a compound of the formula I above, comprising reacting a compound of the formula II
• R 2 , X, Bi and B 2 are as previously defined and Hal is halogen
• the present invention furthermore provides a process for the preparation of a compound of the formula II, comprising reacting a compound of the formula III
• R 2 , X, Bi and B 2 are as previously defined with a compound of the formula IV
• Scheme B provides another general synthetic procedure for preparing compounds of the formula I.
• X O, S, NH or (CH 2 ) n
• n 0 or 1
• step a the appropriate amino compound of structure 28 wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 is reacted with the appropriate (R)-bromoacid of structure 33 to give the corresponding (R)-bromoamide compound of structure 34 wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 under similar conditions as described previously in Scheme A, step g.
• the appropriate amino compound of structure 28 wherein X is O, S, NH or (CH 2 ) ⁇ wherein n is 0 or 1 is reacted with the appropriate (S)-bromoacid to give the corresponding (S)-bromoamide wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 or the appropriate amino compound of structure 28 wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 is reacted with the appropriate enantiomeric mixture of the bromoacid to give the corresponding diastereoisomeric mixture of the bromoamide wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 as described previously in Scheme A, step g.
• step b the (R)-bromo functionality of the appropriate (R)-bromoamide compound of structure 34 wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 is converted to the corresponding (S)-thioacetate or ( S)-thiobenzoate of structure 36, wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1.
• the appropriate (R)-bromoamide compound of structure 34 wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 is reacted with thiolacetic acid or thiolbenzoic acid of structure 35 in the presence of a base, such as cesium or sodium carbonate.
• a base such as cesium or sodium carbonate.
• the reactants are typically contacted in a suitable organic solvent such as a mixture of dimethylformamide and tetrahydrofuran.
• the reactants are typically stirred together at room temperature for a period of time ranging from 1 to 8 hours.
• the bromo functionality of the appropriate diastereoisomeric mixture of the bromoamides described supra wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1 is converted to the corresponding diastereoisomeric mixture of thioacetate or thiobenzoate compounds wherein X is O, S, NH or (CH 2 ) n wherein n is 0 or 1.
• Scheme B provides for the preparation of compounds of formula I wherein the tricyclic moiety has a 4-carboxy functionality of the (S)-configuration when for example X is -CH 2
• the compounds of formula I wherein the carboxy functionality is of the (R)-configuration may be prepared by substituting the appropriate (4R)-carboxy amino compound for the amino compound of structure 28 whose preparation is described in Scheme A.
• step a [4S-[4 ⁇ ,7 ⁇ (S),12b ⁇ ]]-7- [[2(R)-bromo-3-methyl-1-oxobutyl]amino]- 1 ,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1 a][2]benzazepine-4-carboxy!ic acid, diphenylmethyl ester
• Example 2 The crude product produced in Example 2 (3.5 mmol) was dissolved in methylene chloride (6.0 ml) and anisole (1.0 ml), cooled to -50°C and treated with trifluoroacetic acid (6.0 ml). The mixture was allowed to warm to 25°C, stirred for 2 hours, concentrated in vacuo and purified by chromatography (1 :1 ethyl acetate/hexane plus 1 % acetic acid) to give the title compound.
• Example 3 The product obtained in Example 3 (75 mg, 0.17 mmol) was dissolved in 1.0 ml of degassed methanol under nitrogen atmosphere and treated with lithium hydroxide (0.4 ml of a 1N solution). After stirring at 25°C for 1.5 hours, the solution was concentrated in vacuo, diluted with water (2 ml) and acidified with hydrochloric acid (0.5 ml of a 1 N solution). The resultant product was filtered and vacuum dried to give the title compound as a white solid (55 mg, 0.14 mmol, 83%).
• the compounds according to the present invention can be used to treat warm-blooded animals or mammals, including mice, rats and humans, suffering from disease states such as, but not limited to, hypertension, congestive heart failure, cardiac hypertrophy, renal failure, and/or cirrhosis.
• An effective ACE and NEP inhibitory amount of a compound of the formula I is an amount which is effective in inhibiting ACE and NEP which results, for example, in a hypotensive effect.
• An effective ACE and NEP inhibitory dose of a compound of the formula I can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the effective dose, a number of factors are considered including, but not limited to: the species of animal; the animal's size, age and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the dose regimen selected; and the use of concomitant medication.
• An effective dual ACE and NEP inhibitory amount of a compound of the formula I will generally vary from about 0.01 milligram per kilogram body weight per day (mg/kg/day) to about 20 mg/kg/day. A daily dose of from about 0.1 mg/kg to about 10 mg/kg is preferred.
• compounds of Formula I can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes.
• the compound can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, and the like.
• Oral administration is generally preferred.
• One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the disease state to be treated, the stage of the disease, and other relevant circumstances.
• Compounds of formula I can be administered in the form of pharmaceutical compositions or medicaments which are made by combining the compounds of Formula I with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the chosen route of administration, and standard pharmaceutical practice.
• the present invention provides pharmaceutical compositions comprising an effective amount of a compound of Formula I in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.
• the pharmaceutical compositions or medicaments are prepared in a manner well known in the pharmaceutical art.
• the carrier may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art.
• the pharmaceutical composition may be adapted for oral or parental use and may be administered to the patient in the form of tablets, capsules, suppositories, solutions, suspensions, or the like.
• Suitable pharmaceutical carriers and formulation techniques are found in standard texts, such as Remington: The Science and Practice of Pharmacy, 19 th edition, Volumes 1 and 2, 1995, Mack Publishing Co., Easton, Pennsylvania, U.S.A., which is herein incorporated by reference.
• the pharmaceutical compositions may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatine capsules or compressed into tablets.
• the compounds of Formula I may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like.
• compositions should contain at least 4 % of the compound of Formula I, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit.
• the amount of the active ingredient present in compositions is such that a unit dosage form suitable for administration will be obtained.
• the tablets, pills, capsules, troches and the like may also contain one or more of the following adjuvants: binders, such as microcrystalline cellulose, gum tragacanth or gelatine; excipients, such as starch or lactose, disintegrating agents such as alginic acid, Primojel®, corn starch and the like; lubricants, such as magnesium stearate or Sterotex®; glidants, such as colloidal silicon dioxide; and sweetening agents, such as sucrose or saccharin may be added or flavouring agents, such as peppermint, methyl salicylate or orange flavouring.
• binders such as microcrystalline cellulose, gum tragacanth or gelatine
• excipients such as starch or lactose, disintegrating agents such as alginic acid, Primojel®, corn starch and the like
• lubricants such as magnesium stearate or Sterotex®
• glidants such as colloidal silicon dioxide
• sweetening agents such
• the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.
• a liquid carrier such as polyethylene glycol or a fatty oil.
• Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
• tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
• a syrup may contain, in addition to the active ingredient, sucrose as a sweetening agent and certain preservatives, dyes and colourings and flavours. Materials used in preparing these various compositions should be pharmaceutically pure and non toxic in the amounts used.
• the compounds of Formula I may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of a compound of the invention, but may be varied to be between 0.1 and about 50% of the weight thereof. The amount of the active ingredient present in such compositions is such that a suitable dosage will be obtained.
• the solutions or suspensions may also include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
• the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
• the new compounds of the formula I have long-lasting, intensive hypotensive action. Moreover, in patients with heart failure the compounds of the formula I increase cardiac output, decrease Left Ventricular End Diastolic Pressure (LVEDP) and increase coronary flow.
• LVEDP Left Ventricular End Diastolic Pressure
• the exceptionally powerful activity of the compounds according to the formula I is demonstrated by the pharmacological data summarized in Figure 1.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Cephalosporin Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (23)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26246410

Family Applications (1)

Country Status (27)

Cited By (2)

Citations (3)

Family Cites Families (1)

• 2002
  • 2002-04-03 AU AU2002304804A patent/AU2002304804B2/en not_active Ceased
  • 2002-04-03 DE DE60202602T patent/DE60202602T2/de not_active Expired - Lifetime
  • 2002-04-03 MX MXPA03008613A patent/MXPA03008613A/es active IP Right Grant
  • 2002-04-03 BR BR0208889-4A patent/BR0208889A/pt not_active Application Discontinuation
  • 2002-04-03 EE EEP200300500A patent/EE05272B1/xx not_active IP Right Cessation
  • 2002-04-03 SK SK1255-2003A patent/SK287616B6/sk not_active IP Right Cessation
  • 2002-04-03 RU RU2003132875/04A patent/RU2286346C2/ru not_active IP Right Cessation
  • 2002-04-03 ES ES02732549T patent/ES2232752T3/es not_active Expired - Lifetime
  • 2002-04-03 EP EP02732549A patent/EP1381605B1/en not_active Expired - Lifetime
  • 2002-04-03 CN CNB028081005A patent/CN1245404C/zh not_active Expired - Fee Related
  • 2002-04-03 SI SI200230089T patent/SI1381605T1/xx unknown
  • 2002-04-03 OA OA1200300267A patent/OA12502A/fr unknown
  • 2002-04-03 WO PCT/EP2002/003668 patent/WO2002083671A1/en active IP Right Grant
  • 2002-04-03 CZ CZ20032722A patent/CZ299708B6/cs not_active IP Right Cessation
  • 2002-04-03 IL IL15828902A patent/IL158289A0/xx unknown
  • 2002-04-03 CA CA2443488A patent/CA2443488C/en not_active Expired - Fee Related
  • 2002-04-03 PL PL363034A patent/PL209338B1/pl unknown
  • 2002-04-03 NZ NZ528825A patent/NZ528825A/en not_active IP Right Cessation
  • 2002-04-03 JP JP2002581426A patent/JP4392167B2/ja not_active Expired - Fee Related
  • 2002-04-03 AT AT02732549T patent/ATE286898T1/de active
  • 2002-04-03 HU HU0303482A patent/HU229612B1/hu not_active IP Right Cessation
  • 2002-04-03 PT PT02732549T patent/PT1381605E/pt unknown
• 2003
  • 2003-09-16 MA MA27312A patent/MA26098A1/fr unknown
  • 2003-09-26 BG BG108203A patent/BG66387B1/bg unknown
  • 2003-10-02 NO NO20034412A patent/NO325655B1/no not_active IP Right Cessation
  • 2003-10-10 HR HR20030823A patent/HRP20030823B1/xx not_active IP Right Cessation
• 2004
  • 2004-07-02 HK HK04104739A patent/HK1061690A1/xx not_active IP Right Cessation

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events